Off-label use of rituximab for systemic lupus erythematosus in Europe

OBJECTIVES: Rituximab (RTX) is a biological treatment used off-label in patients with systemic lupus erythematosus (SLE). This survey aimed to investigate the off-label use of RTX in Europe and compare the characteristics of patients receiving RTX with those receiving conventional therapy. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Rydén-Aulin, Monica, Boumpas, Dimitrios, Bultink, Irene, Callejas Rubio, Jose Luis, Caminal-Montero, Luis, Castro, Antoni, Colodro Ruiz, Agustín, Doria, Andrea, Dörner, Thomas, Gonzalez-Echavarri, Cristina, Gremese, Elisa, Houssiau, Frederic A, Huizinga, Tom, Inanç, Murat, Isenberg, David, Iuliano, Annamaria, Jacobsen, Søren, Jimenéz-Alonso, Juan, Kovács, Lászlo, Mariette, Xavier, Mosca, Marta, Nived, Ola, Oristrell, Joaquim, Ramos-Casals, Manuel, Rascón, Javier, Ruiz-Irastorza, Guillermo, Sáez-Comet, Luis, Salvador Cervelló, Gonzalo, Sebastiani, Gian Domenico, Squatrito, Danilo, Szücs, Gabriella, Voskuyl, Alexandre, van Vollenhoven, Ronald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2016
Materias:
Epidemiology and Outcomes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5013507/
https://www.ncbi.nlm.nih.gov/pubmed/27651920
http://dx.doi.org/10.1136/lupus-2016-000163

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5013507/
https://www.ncbi.nlm.nih.gov/pubmed/27651920
http://dx.doi.org/10.1136/lupus-2016-000163

Ejemplares similares